Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development
新顾问委员会成员将首先聚焦Venowave销售和业务拓展
Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in sales and operations within the medical and pharmaceutical industries to its advisory board.
加拿大安大略省多伦多,2024年8月13日--(Newsfile Corp. - 2024年8月13日) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma"或“公司”)是领先的诊断和医疗器械技术的开发商和投资合作伙伴之一,公司很高兴宣布已将已经在医疗和制药行业的销售和运营进行了30年的Michael Raimondo添加到其顾问委员会。
With more than three (3) decades of experience, Mr. Raimondo brings to the table extensive leadership experience including numerous accomplishments in developing industry-leading strategic account organizations that have delivered customer-centric solutions to healthcare systems across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over $500 million in sales contracts.
Michael Raimondo拥有三十年以上的经验,具有广泛的领导和经验,包括在发展行业领先的战略账户组织方面取得的众多成就,这些成就为美国各地的医疗保健系统提供了以患者为中心的解决方案。Michael Raimondo擅长销售谈判,成功地签订了超过5,000万美元的销售合同。
Michael is a current Board of Advisor for Marketsmith, one of the country's (US) largest woman-owned and operated independent media and marketing agencies. He also is a Managing Partner of The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.
Michael目前是Marketsmith的顾问委员会成员,Marketsmith是美国最大的女性拥有和经营的独立媒体和营销机构之一。他还是The Potentia Group的管理合伙人,该公司专门从事美国医疗保健市场内的谈判培训、销售领导发展和咨询工作。Michael拥有库茨敦大学物理学学士学位和数学副修,曾在俄亥俄、肯塔基和印第安纳地区的美国愿望基金会担任董事会成员。
"We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the Company's sales efforts of its health-tech and med-tech devices, including Venowave," shared Rob Fia, CEO of Therma Bright. "With our Venowave's pending approval on patient reimbursement permanent codes from the U.S. Centers of Medicare and Medicaid (CMS) and a handful of value-added reseller partners ready to engage their medical practitioner networks, we believe Michael will help expand these efforts and open more doors with other reseller partners across the U.S."
"我们很高兴Michael同意加入Therma Bright的顾问委员会,在公司的医疗科技和医疗技术设备销售方面,他在销售和运营方面的技能和经验将有助于我们的销售工作,包括Venowave," Therma Bright的首席执行官Rob Fia分享道。"随着我们Venowave等待美国医疗保险和医疗补助中心(CMS)对患者费用报销永久代码的批准,并有少数增值经销商合作伙伴准备与其医疗从业人员网络互动,我们相信Michael将帮助扩大这些努力,并与美国的其他增值经销商合作伙伴取得更多机会。"
"I am excited to join Therma Bright's Advisory Board, and bring my sales, business development and operations experience to the Company," expressed Michael Raimondo. "With over 30 years of experience in medical and pharmaceutical industries, I am confident in my abilities to help grow the Company's value-added resellers across America to bring new, innovative solutions, like Venowave, to patient suffering from various pains and ailments, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."
"我很高兴加入Therma Bright的顾问委员会,并将我的销售,业务发展和运营经验注入公司," Michael Raimondo表示。"在医药行业拥有超过30年的经验,我对自己在帮助公司增值经销商推广全美新的创新解决方案,如Venowave,让各种疼痛和疾病的患者受益充满信心,个例如CDC透露每年900,000名公民患有深静脉血栓形成。"
Mr. Raimondo is taking on his advisory role at Therma Bright with great enthusiasm and has already begun actively tapping into his network to introduce Venowave pre-CMS approval.
Raimondo先生充满热情地接受了Therma Bright的顾问角色,并已开始积极利用他的关系网络,在CMS批准Venowave之前介绍Venowave。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.简介:Therma Bright是一家开发商和合作伙伴,在各种领先的专有诊断和医疗器械技术方面致力于为消费者和医疗专业人士提供质量卓越,创新的解决方案,以应对当今最重要的医疗和医疗保健挑战。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。访问:。
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席执行官
rfia@thermabright.com
rfia@thermabright.com
关注我们的Twitter账号
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
前瞻性声明
本新闻稿中的某些声明构成"前瞻性"声明。这些声明涉及未来事件和相关信息,例如新闻稿中描述的Venowave的未来销售。所有这些声明涉及重大的已知和未知的风险、不确定因素和其他因素,这些因素可能导致实际结果与此类前瞻性声明所表达或暗示的结果不同。前瞻性声明涉及重大风险和不确定性,不应被视为未来业绩或结果的保证,它们不一定是这些结果的准确指标。由于多种因素和风险的影响,实际结果可能与管理层认为的合理假设不一致。本新闻稿中包含的前瞻性声明基于本公司管理层于本新闻稿发布日所认为的合理假设,本公司无法保证投资者实际结果将与这些前瞻性声明一致。本新闻稿中包含的前瞻性声明是截至本日期的声明,本公司否认任何意向或义务更新或修订任何前瞻性声明,无论是基于新信息、未来事件还是其他因素,除非适用的证券法规要求。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其监管服务提供商(如TSX Venture Exchange政策中所定义)对本新闻稿的充分性或准确性不承担责任。